Following a brief discussion of the shortcomings of the buy-and-bill model in oncology, Michael Kolodziej, MD, and Brian Kiss, MD, describe the origins of the model and suggest changes needed based on the evolution of healthcare reimbursement strategies in the United States.
Dr Kolodziej defends the buy-and-bill model, explaining that it originated in the 1980s as a way for practices to help pay for the infrastructure needed for cancer care to be delivered in the community setting rather than in the hospital setting.
Because treatment options in oncology have evolved and oral oncolytics that can be dispensed via practice-based pharmacies are now available, adds Dr Kiss, the latest challenge is determining how to compensate oncologists fairly given the introduction of oral drugs.
Resolving these issues will require agreement and collaboration among multiple stakeholders in healthcare, Dr Kolodziej remarks.
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More